Effects of chronic treatment of rats with "designer" amphetamines on brain regional monoamines.
(+)-Amphetamine and two structurally related analogues, 4-methoxyamphetamine and a recent "designer drug," 4-ethoxyamphetamine, were given to rats via subcutaneous osmotic minipumps for 1-14 days. Regional brain levels of the drugs as well as monoamine neurotransmitters and some of their major acidic metabolites were determined. Amphetamine produced depletions of dopamine in the striatum after at least 3 days of treatment but not in the nucleus accumbens of olfactory tubercle, even after 14 days of treatment. In contrast, the two ring-substituted amphetamine analogues increased levels of the monoamines and decreased levels of their acid metabolites. These data indicate that the two ring-substituted amphetamine analogues, at least one of which is a potent hallucinogen, have potent monoamine oxidase inhibition properties that are sustained during chronic treatment. Furthermore, these two compounds do not share amphetamine's regionally selective neurotoxic effects on dopamine-releasing terminals, even though brain and striatal drug levels are the same or higher than those of amphetamine.
Martin-Iverson
M T
MT
Department of Psychiatry, Mackenzie Health Sciences Centre, University of Alberta, Edmonton, Canada.
Lodge
B A
BA
D000662:Amphetamines / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D015198:Designer Drugs; D003913:Dextroamphetamine / Q000633:toxicity; D006213:Hallucinogens / Q000633:toxicity; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D014018:Tissue Distribution
D000662:Amphetamines; D015306:Biogenic Monoamines; D015198:Designer Drugs; D006213:Hallucinogens; C065948:4-ethoxyamphetamine; C100230:4-methoxyamphetamine; D003913:Dextroamphetamine